|
|
Volumn 23, Issue S1, 2015, Pages S7-S11
|
|
Safety and tolerability of medications approved for chronic weight management
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMFEBUTAMONE PLUS NALTREXONE;
LIRAGLUTIDE;
LORCASERIN;
PHENTERMINE PLUS TOPIRAMATE;
TETRAHYDROLIPSTATIN;
AMFEBUTAMONE;
ANTIOBESITY AGENT;
BENZAZEPINE DERIVATIVE;
DELAYED RELEASE FORMULATION;
FRUCTOSE;
GLUCAGON LIKE PEPTIDE 1;
NALTREXONE;
NEW DRUG;
PHENTERMINE;
TOPIRAMATE;
BODY MASS;
CHRONIC DISEASE;
DRUG APPROVAL;
DRUG CONTRAINDICATION;
DRUG FORMULATION;
DRUG MARKETING;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG USE;
HUMAN;
OBESITY;
PRACTICE GUIDELINE;
PRESCRIPTION;
REVIEW;
TREATMENT INDICATION;
WEIGHT REDUCTION;
ADVERSE DRUG REACTION;
ANALOGS AND DERIVATIVES;
DELAYED RELEASE FORMULATION;
DRUG EFFECTS;
FOOD AND DRUG ADMINISTRATION;
UNITED STATES;
ANTI-OBESITY AGENTS;
BENZAZEPINES;
BUPROPION;
DELAYED-ACTION PREPARATIONS;
DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;
DRUGS, INVESTIGATIONAL;
FRUCTOSE;
GLUCAGON-LIKE PEPTIDE 1;
HUMANS;
NALTREXONE;
OBESITY;
PHENTERMINE;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
WEIGHT LOSS;
|
|
EID: 84928104942
PISSN: 19307381
EISSN: 1930739X
Source Type: Journal
DOI: 10.1002/oby.21094 Document Type: Review |
|
Times cited : (34)
|
|
References (5)
|
